Crinetics公布Palsonify强劲上市表现及Atumelnant治疗先天性肾上腺皮质增生症二期试验中雄烯二酮降低与糖皮质激素减量并行的积极结果

美股速递
Jan 05

Crinetics Pharmaceuticals Inc.宣布其药物Palsonify的上市执行表现强劲,同时在Atumelnant用于治疗先天性肾上腺皮质增生症的二期临床试验中,取得了降低雄烯二酮与减少糖皮质激素剂量并行的积极成果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10